OBJECTIVETo evaluate the long-time effect on allitridum and selenium in preventing cancer of digestive system.

METHODSPersons who were recruited into the intervention group and took allitridum and selenium to prevent gastric cancer in Qixia county of China from 1989-1991 were followed up to 2001 and data of deaths was collected. The long effect on allitridum and selenium in preventing cancer of digestive system was analysed.

RESULTSData were compared to placebo group five years (1992-1996) after the termination of intervention to have found that the accumulative mortality rate of all cancer, digestive system cancer and gastric cancer had decreased 45.5%, 41.2% and 63.3% in the intervention group respectively. By stratum analysis, accumulative mortality rate of all cancer, digestive system cancer and gastric cancer had decreased 51.5%, 51.5% and 67.7% in males of the intervention group, respectively. Relative risks for males in the intervention group were 0.48, 0.47 and 0.30 times more than the placebo group, respectively. All of them were statistically significant. Relative risks for females in the intervention group were 0.74, 0.92 and 0.70 times more than placebo group. Six to ten years later after the termination of intervention, the accumulative mortality rate and relative risk of all cancers in two groups became similar.

CONCLUSIONAllitridum and selenium had the effect of decreasing the incidence risk of digestive cancer with a protective rate more than 50% for five years after the termination of intervention program.

Adult ; Aged ; Allyl Compounds ; therapeutic use ; Antioxidants ; therapeutic use ; Female ; Follow-Up Studies ; Gastrointestinal Neoplasms ; prevention & control ; Humans ; Male ; Middle Aged ; Selenium ; therapeutic use ; Stomach Neoplasms ; prevention & control ; Sulfides ; therapeutic use

BACKGROUNDPeople have more and more concerned about allitridum as studies have shown that taking more raw garlic associated with a lower risk for cancers of the alimentary system. In the present study, we tried to examine whether a large dose of allitridum and a microdose of selenium prevent gastric cancer.

METHODSA double-blind intervention study was performed on the participants aged (35 - 74) years, who had matched at least one of the following criteria: (1) a medical history of stomach disorder, (2) a family history of tumour, or (3) smoking and/or alcohol consumption. A total of 2,526 and 2,507 persons were randomly enrolled into intervention group and control group respectively from 288 natural villages of seven communities in Qixia County, Shandong Province, China. Each person of the intervention group orally took 200 mg synthetic allitridum every day and 100 microg selenium every other day for one month of each year during November 1989 to December 1991. At the same time, people in control group were given 2 placebo capsules containing corn oid with the identical appearance to that in the intervention group.

RESULTSFor all subjects the large dose of allitridum was accepted and no harmful side effects were found during the study. In the first follow-up five years (1992 - 1997) after stopping the intervention, the morbidity rates of malignant tumours in the intervention group declined by 22%, in contrast to the control group, declined by 47.3%. After adjusting for age, gender, and other potential confounders, relative risks (RRs) for all tumours and gastric cancer of the whole population were 0.67 (95% CL: 0.43 - 1.03) and 0.48 (95% CL: 0.21 - 1.06), respectively, and for male group they were 0.51 (95% CL: 0.30 - 0.85) and 0.36 (95% CL: 0.14 - 0.92), respectively. No signigicantly protective effect was found for the female subgroup.

CONCLUSIONThe present study proves that large doses of allitridum and microdorse of selenium may effectively prevent gastric cancer, especially in men.

Adult ; Aged ; Allyl Compounds ; administration & dosage ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Multivariate Analysis ; Selenium ; administration & dosage ; Stomach Neoplasms ; prevention & control ; Sulfides ; administration & dosage

Objective: Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear. Methods: A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients' medical records. Multivariable logistic regression models were used to estimate the odds ratio ( Results: Overall, 158 (13.6%) patients were diagnosed with severe illness and 32 (2.7%) had unfavorable outcomes. Hypertension (2.87, 1.30-6.32), type 2 diabetes (T2DM) (3.57, 2.32-5.49), cardiovascular disease (CVD) (3.78, 1.81-7.89), fatty liver disease (7.53, 1.96-28.96), hyperlipidemia (2.15, 1.26-3.67), other lung diseases (6.00, 3.01-11.96), and electrolyte imbalance (10.40, 3.00-26.10) were independently linked to increased odds of being severely ill. T2DM (6.07, 2.89-12.75), CVD (8.47, 6.03-11.89), and electrolyte imbalance (19.44, 11.47-32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission (5.46, 3.25-9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes (6.58, 1.46-29.64) within two weeks. Conclusion Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.
Adult ; Aged ; COVID-19/virology* ; China/epidemiology* ; Comorbidity ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome